|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LY6E |
Gene summary for LY6E |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LY6E | Gene ID | 4061 |
| Gene name | lymphocyte antigen 6 family member E | |
| Gene Alias | RIG-E | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | Q16553 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4061 | LY6E | GSM4909281 | Human | Breast | IDC | 2.98e-102 | 1.14e+00 | 0.21 |
| 4061 | LY6E | GSM4909282 | Human | Breast | IDC | 1.34e-05 | 3.62e-01 | -0.0288 |
| 4061 | LY6E | GSM4909285 | Human | Breast | IDC | 3.26e-05 | 3.42e-01 | 0.21 |
| 4061 | LY6E | GSM4909286 | Human | Breast | IDC | 2.97e-10 | -2.35e-01 | 0.1081 |
| 4061 | LY6E | GSM4909287 | Human | Breast | IDC | 3.34e-21 | 5.74e-01 | 0.2057 |
| 4061 | LY6E | GSM4909290 | Human | Breast | IDC | 2.46e-03 | -2.63e-01 | 0.2096 |
| 4061 | LY6E | GSM4909291 | Human | Breast | IDC | 4.49e-03 | 4.05e-01 | 0.1753 |
| 4061 | LY6E | GSM4909294 | Human | Breast | IDC | 2.66e-02 | -2.60e-01 | 0.2022 |
| 4061 | LY6E | GSM4909296 | Human | Breast | IDC | 4.18e-27 | 4.97e-01 | 0.1524 |
| 4061 | LY6E | GSM4909297 | Human | Breast | IDC | 2.56e-21 | 2.91e-01 | 0.1517 |
| 4061 | LY6E | GSM4909299 | Human | Breast | IDC | 5.70e-15 | 4.91e-01 | 0.035 |
| 4061 | LY6E | GSM4909300 | Human | Breast | IDC | 2.39e-07 | 5.47e-01 | 0.0334 |
| 4061 | LY6E | GSM4909304 | Human | Breast | IDC | 3.35e-26 | 5.97e-01 | 0.1636 |
| 4061 | LY6E | GSM4909305 | Human | Breast | IDC | 2.12e-22 | 6.96e-01 | 0.0436 |
| 4061 | LY6E | GSM4909306 | Human | Breast | IDC | 1.22e-03 | 3.10e-01 | 0.1564 |
| 4061 | LY6E | GSM4909307 | Human | Breast | IDC | 6.29e-06 | 3.73e-01 | 0.1569 |
| 4061 | LY6E | GSM4909309 | Human | Breast | IDC | 2.71e-38 | 7.91e-01 | 0.0483 |
| 4061 | LY6E | GSM4909311 | Human | Breast | IDC | 4.82e-34 | 1.07e-01 | 0.1534 |
| 4061 | LY6E | GSM4909312 | Human | Breast | IDC | 5.86e-18 | 4.10e-01 | 0.1552 |
| 4061 | LY6E | GSM4909313 | Human | Breast | IDC | 1.18e-11 | 2.81e-01 | 0.0391 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
| GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
| GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
| GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
| GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
| GO:00507929 | Breast | Precancer | regulation of viral process | 27/1080 | 164/18723 | 7.59e-07 | 3.05e-05 | 27 |
| GO:00444099 | Breast | Precancer | entry into host | 25/1080 | 151/18723 | 1.74e-06 | 6.19e-05 | 25 |
| GO:00467189 | Breast | Precancer | viral entry into host cell | 24/1080 | 144/18723 | 2.46e-06 | 8.35e-05 | 24 |
| GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
| GO:00439039 | Breast | Precancer | regulation of biological process involved in symbiotic interaction | 15/1080 | 72/18723 | 1.23e-05 | 3.17e-04 | 15 |
| GO:19039009 | Breast | Precancer | regulation of viral life cycle | 23/1080 | 148/18723 | 1.31e-05 | 3.30e-04 | 23 |
| GO:00523727 | Breast | Precancer | modulation by symbiont of entry into host | 12/1080 | 49/18723 | 1.61e-05 | 3.93e-04 | 12 |
| GO:00465964 | Breast | Precancer | regulation of viral entry into host cell | 11/1080 | 42/18723 | 1.83e-05 | 4.35e-04 | 11 |
| GO:19039014 | Breast | Precancer | negative regulation of viral life cycle | 7/1080 | 25/18723 | 4.00e-04 | 5.42e-03 | 7 |
| GO:0046597 | Breast | Precancer | negative regulation of viral entry into host cell | 6/1080 | 21/18723 | 9.31e-04 | 1.06e-02 | 6 |
| GO:00017017 | Breast | Precancer | in utero embryonic development | 35/1080 | 367/18723 | 2.47e-03 | 2.27e-02 | 35 |
| GO:00605374 | Breast | Precancer | muscle tissue development | 37/1080 | 403/18723 | 3.60e-03 | 2.98e-02 | 37 |
| GO:00147063 | Breast | Precancer | striated muscle tissue development | 35/1080 | 384/18723 | 5.10e-03 | 3.83e-02 | 35 |
| GO:00485255 | Breast | Precancer | negative regulation of viral process | 12/1080 | 92/18723 | 6.51e-03 | 4.51e-02 | 12 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LY6E | SNV | Missense_Mutation | rs368130997 | c.59N>T | p.Ser20Leu | p.S20L | Q16553 | protein_coding | deleterious(0.02) | benign(0.011) | TCGA-LL-A740-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| LY6E | SNV | Missense_Mutation | novel | c.282N>C | p.Gln94His | p.Q94H | Q16553 | protein_coding | deleterious(0.04) | probably_damaging(0.933) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| LY6E | SNV | Missense_Mutation | novel | c.217N>A | p.Pro73Thr | p.P73T | Q16553 | protein_coding | deleterious(0.02) | possibly_damaging(0.822) | TCGA-AA-3522-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| LY6E | SNV | Missense_Mutation | c.167N>A | p.Gly56Asp | p.G56D | Q16553 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LY6E | SNV | Missense_Mutation | c.392C>A | p.Pro131His | p.P131H | Q16553 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.75) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LY6E | SNV | Missense_Mutation | rs777594710 | c.218N>T | p.Pro73Leu | p.P73L | Q16553 | protein_coding | deleterious(0.01) | benign(0.052) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LY6E | SNV | Missense_Mutation | novel | c.350N>T | p.Gly117Val | p.G117V | Q16553 | protein_coding | tolerated(0.06) | possibly_damaging(0.851) | TCGA-NJ-A55A-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LY6E | SNV | Missense_Mutation | novel | c.208A>G | p.Thr70Ala | p.T70A | Q16553 | protein_coding | tolerated(0.18) | benign(0) | TCGA-37-4132-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| LY6E | SNV | Missense_Mutation | novel | c.221N>T | p.Ala74Val | p.A74V | Q16553 | protein_coding | tolerated(0.92) | benign(0) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |